Dakota Wealth Management’s Corcept Therapeutics CORT Stock Holding History

Dakota Wealth Management’s Portfolio CORT Stock Details CORT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.63M	Hold	30,200	–	–	0.05%	261
2026 Q1	$1.22M	Hold	30,200	–	–	0.03%	367
2025 Q4	$1.05M	Hold	30,200	–	–	0.02%	397
2025 Q3	$2.51M	Hold	30,200	–	–	0.05%	228
2025 Q2	$2.22M	Hold	30,200	–	–	0.05%	254
2025 Q1	$3.45M	Hold	30,200	–	–	0.08%	181
2024 Q4	$1.52M	Hold	30,200	–	–	0.04%	298
2024 Q3	$1.4M	Hold	30,200	–	–	0.03%	316
2024 Q2	$981K	Hold	30,200	–	–	0.02%	376
2024 Q1	$761K	Hold	30,200	–	–	0.02%	419
2023 Q4	$981K	Hold	30,200	–	–	0.04%	314
2023 Q3	$823K	Hold	30,200	–	–	0.04%	319
2023 Q2	$672K	Hold	30,200	–	–	0.03%	327
2023 Q1	$654K	Hold	30,200	–	–	0.04%	305
2022 Q4	$613K	Hold	30,200	–	–	0.04%	316
2022 Q3	$774K	Buy	+30,200	New	+$808K	0.06%	250

Other funds holding CORT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ISL

Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Dakota Wealth Management's CORT Position: Q2 2026 in Review

Dakota Wealth Management held its Corcept Therapeutics (CORT) position steady in Q2 2026 at 30,200 shares worth $2.63M. The position accounts for 0.05% of the portfolio, ranked #261.

Dakota Wealth Management first reported a position in CORT in Q3 2022 and has held it in 16 quarters since. The position peaked at $3.45M in Q1 2025. 423 funds tracked by Wall St. Rank hold CORT as of Q2 2026.

Dakota Wealth Management held 30,200 shares of Corcept Therapeutics worth $2.63M as of Q2 2026.
Dakota Wealth Management left its Corcept Therapeutics share count unchanged in Q2 2026.
Corcept Therapeutics made up 0.05% of Dakota Wealth Management's portfolio in Q2 2026, its #261 holding.
Dakota Wealth Management first reported a position in Corcept Therapeutics in Q3 2022 and has held it in 16 quarters since.
Dakota Wealth Management's Corcept Therapeutics position peaked at $3.45M in Q1 2025.
423 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2026.

Based on Dakota Wealth Management's 13F filing for Q2 2026, filed 7 Aug 2026.